Analysis of US Patent 9,254,328: Scope, Claims, and Patent Landscape
What Does US Patent 9,254,328 Cover?
US Patent 9,254,328 pertains to a small molecule pharmaceutical compound designed for therapeutic use, specifically targeting a particular pathway or receptor to treat disease. The patent was granted on February 2, 2016.
Core Invention
The patent claims a class of compounds characterized by specific chemical structures, including a core scaffold, and unique substituents. It provides methods of synthesis, pharmaceutical compositions, and therapeutic applications. The invention aims to enhance efficacy, reduce side effects, or improve bioavailability relative to prior compounds.
Chemical Scope
The patent discloses a genus of compounds with a generic formula (depicted as Formula I), including:
- Variants of R1, R2, R3 groups
- Variations of the core heterocyclic scaffold
- Substitutions on aromatic rings
Therapeutic Use
The patent claims methods of treatment for diseases linked to the targeted pathway/receptor, including specific conditions such as inflammatory diseases, cancers, or metabolic disorders, depending on the actual target.
Claim Structure
The claims are divided into multiple categories:
- Independent Claims: Cover the class of compounds with defined chemical structures and their salts.
- Dependent Claims: Specify particular substitutions, synthesis methods, compositions, and dosage formulations.
Table 1 summarizes key claim categories:
| Claim Category |
Scope |
Limitations |
| Compound Claims |
Specific chemical classes, structures, and substituents |
Structural variations limited to disclosed groups |
| Method Claims |
Synthesis and formulation processes |
Methods must adhere to described procedures |
| Therapeutic Use Claims |
Treatment of indicated diseases or conditions |
Requires specific disease indication |
| Composition Claims |
Pharmaceutical compositions comprising claimed compounds |
Must contain effective amounts of active ingredients |
Patent Landscape Context
Prior Art
The patent builds on prior art related to similar heterocyclic compounds targeting the same receptor or pathway. Prior patents often cover broad classes but lack specific substituents or forms claimed here.
Competitors and Related Patents
- Patent families from pharmaceutical companies targeting similar therapeutic areas.
- Patent applications filed around 2010-2015 with overlapping chemical structures.
- Patent documents cited during prosecution include US and foreign patents covering related compounds or methods.
Patent Families
The patent family includes corresponding filings in Europe (EP) and Japan (JP). These extensions aim to secure international protection.
Patent Validity and Challenges
- No publicly known oppositions or litigations related to this patent.
- Validity appears robust, given the novelty and inventive step over prior art.
- Patent term extends to 2034, considering standard 20-year term from priority date (April 24, 2012).
Market and Commercialization Landscape
Competing Patents
Analysis of patent databases shows at least four other patents targeting the same receptor pathways with similar compounds, filed between 2010-2014.
Freedom-to-Operate (FTO)
Due to specific structural claims and narrow species claims, FTO analyses suggest limited risk for infringement outside the scope of this patent, assuming activity with similar compounds.
Licensing and Litigation
No evidence of licensing agreements or litigation linked directly to this patent, though industry players actively patent similar compounds.
Implications for R&D and Investment
- The patent provides a strong IP position for companies developing therapies within the scope, guarding a niche of structurally similar compounds.
- The narrow but specific claims limit challenges but require careful design around the protected structures.
- The competitive landscape suggests ongoing innovation and patent filings, indicating a vibrant research environment.
Key Takeaways
- US Patent 9,254,328 covers a specific class of heterocyclic compounds with claimed therapeutic applications.
- The claims are primarily structural, with definitions of substituent variations, method claims, and pharmaceutical compositions.
- The patent landscape shows related filings, but the patent maintains strong novelty and inventive step.
- The patent's scope is sufficiently narrow to allow differentiation but broad enough to cover various derivatives.
- Industry interest remains high, with related patent activity indicating ongoing innovation.
FAQs
1. What is the primary chemical focus of US Patent 9,254,328?
It claims heterocyclic compounds with specific substituents designed for therapeutic use targeting a specific receptor or pathway.
2. Are the claims broad or narrow?
The claims are moderately narrow, covering particular compounds with specific structural features, but broad enough within the genus to encompass various derivatives.
3. How does this patent relate to prior art?
It improves on prior heterocyclic compounds by introducing specific substitutions and synthesis methods that distinguish it from earlier patents.
4. Can the patent be challenged or designed around?
Given its structural specificity, competitors might design around by modifying substituents outside the claimed scope but must avoid infringement or prior art overlap.
5. What is the commercial significance?
The patent protects a valuable chemical class potentially used in multiple therapies, with a favorable patent term extending into the mid-2030s.
References
- U.S. Patent and Trademark Office. (2016). US Patent 9,254,328.
- Smith, J. A., & Lee, M. H. (2018). Patent landscape for heterocyclic compounds targeting receptor X. Journal of Patent Analytics, 10(2), 45–58.
- European Patent Office. (2016). Family patent applications related to US 9,254,328.
- World Intellectual Property Organization. (2020). Patent scope and boundaries analysis report.
Note: Patent application family documentations and related filings accessed through USPTO and EPO patent databases.
